Buderer Drug Co. is not only a provider of customized medications but also an active participant in pharmaceutical research and development. Under the leadership of Matthew J. Buderer, R.Ph., FIACP, the company has contributed to the development of new drugs aimed at improving patient care.
The company’s research initiatives include preparing medications for FDA Phase 1 and Phase 2 clinical trials. This involvement ensures that emerging therapies are both safe and effective for patient use. Additionally, Buderer Drug Co. has collaborated with pharmaceutical companies to develop innovative dosage forms and formulations, furthering advancements in the biotech and over-the-counter drug industries.
Matthew Buderer’s contributions to the field are noteworthy, with publications in peer-reviewed journals and multiple drug patent submissions. His leadership exemplifies the company’s commitment to advancing medical science and providing cutting-edge solutions for patients. To learn more about their research and development efforts, visit their website.
